American Association for Cancer Research
Browse
- No file added yet -

Supplementary Data from Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma

Download (21.65 kB)
journal contribution
posted on 2023-03-31, 22:13 authored by Erik Ladomersky, Lijie Zhai, Kristen L. Lauing, April Bell, Jiahui Xu, Masha Kocherginsky, Bin Zhang, Jennifer D. Wu, Joseph R. Podojil, Leonidas C. Platanias, Aaron Y. Mochizuki, Robert M. Prins, Priya Kumthekar, Jeffrey J. Raizer, Karan Dixit, Rimas V. Lukas, Craig Horbinski, Min Wei, Changyou Zhou, Graham Pawelec, Judith Campisi, Ursula Grohmann, George C. Prendergast, David H. Munn, Derek A. Wainwright

Supplementary Materials and Methods

Funding

NIH

BrainUp

History

ARTICLE ABSTRACT

Wild-type isocitrate dehydrogenase–expressing glioblastoma (GBM) is the most common and aggressive primary brain tumor with a median age at diagnosis of ≥65 years. It accounts for approximately 90% of all GBMs and has a median overall survival (OS) of <15 months. Although immune checkpoint blockade (ICB) therapy has achieved remarkable survival benefits in a variety of aggressive malignancies, similar success has yet to be achieved for GBM among phase III clinical trials to date. Our study aimed to understand the relationship between subject age and immunotherapeutic efficacy as it relates to survival from glioma. (i) Clinical data: GBM patient datasets from The Cancer Genome Atlas, Northwestern Medicine Enterprise Data Warehouse, and clinical studies evaluating ICB were stratified by age and compared for OS. (ii) Animal models: young, middle-aged, and older adult wild-type and indoleamine 2,3 dioxygenase (IDO)-knockout syngeneic mice were intracranially engrafted with CT-2A or GL261 glioma cell lines and treated with or without CTLA-4/PD-L1 mAbs, or radiation, anti–PD-1 mAb, and/or a pharmacologic IDO enzyme inhibitor. Advanced age was associated with decreased GBM patient survival regardless of treatment with ICB. The advanced age–associated increase of brain IDO expression was linked to the suppression of immunotherapeutic efficacy and was not reversed by IDO enzyme inhibitor treatment. Immunosuppression increases in the brain during advanced age and inhibits antiglioma immunity in older adults. Going forward, it will be important to fully understand the factors and mechanisms in the elderly brain that contribute to the decreased survival of older patients with GBM during treatment with ICB.

Usage metrics

    Clinical Cancer Research

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC